ADX-914-203 Enrolling

Severe Alopecia Areata Research Trial (56 Weeks)


Treatment: Injection Age: 18 Years


Who Can Participate?

Adults 18-75 years with a diagnosis of severe or very severe alopecia areata (AA) may participate.

Eligibility Criteria

  • Clinical diagnosis of severe or very severe AA (50% or more total scalp hair loss)
  • Current episode of hair loss has been for more than 6 months (but less than 4 years)
  • No history or presence of hair transplants
  • Willingness to keep the same hair style and color (eg. Hair products, process, and timing of hair appointments) for the study’s duration

 What is Included?

  • No cost to participate or receive study treatment
  • Regular visits with study doctors who specialize in treating AA (26 visits)
  • May receive an investigative injection treatment (study drug)
  • Reimbursement for study-related expenses may be provided

How Long Will The Study Last?

  • 56 weeks

Note: Participants may not be engaged in any other kind of systemic, topical, or device-based therapy for AA.


Participating Locations

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: April 16, 2025

Official Title

A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial With Part B Open-label Extension of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

ClinicalTrials.gov ID

NCT06018428

Sponsor

Q32 Bio Inc.

Study Description

  • Brief Summary:

    Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation. Part B is a multicenter, open-label study to assess the efficacy, safety, and tolerability of bempikibart (ADX-914) in participants with severe Alopecia Areata.

  • Condition or Disease:

    Alopecia Areata

  • Intervention/Treatment:

    Drug: bempikibart (ADX-914)
  • Phase:

    PHASE 2

  • Ages Eligible for Study:

    18 Years and 75 Years (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Alopecia Areata

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content